Related Experiment Videos
[Circulating "tumor markers" in gastrointestinal tumors]
1Med. Klinik II, Universität München.
Leber, Magen, Darm
|September 1, 1991
Summary
Circulating tumor markers (TM) aid in monitoring cancer patients but lack sensitivity for screening. Follow-up measurements are crucial for assessing disease progression and treatment effectiveness in symptomatic individuals.
Area of Science:
- Oncology
- Biochemistry
- Clinical Diagnostics
Context:
- Circulating tumor markers (TM) are shed by neoplastic cells into body fluids.
- Clinically relevant TM are primarily used for monitoring symptomatic cancer patients, not for screening asymptomatic individuals due to insufficient sensitivity and specificity.
Purpose:
- To review the clinical significance and application of circulating tumor markers in oncology.
- To highlight the importance of follow-up measurements over single determinations in patient monitoring.
- To emphasize that TM testing should be guided by diagnostic or therapeutic consequences.
Summary:
- Key circulating TM for gastrointestinal cancers include CEA, AFP, CA 19-9, and CA 72-4.
- AFP is primary for hepatocellular carcinoma, CEA for colorectal cancer, and CA 19-9 for pancreatic cancer.
- Elevated TM can occur in benign liver, pancreas, and bowel diseases, necessitating careful interpretation.
Impact:
- Provides guidance on the appropriate use of tumor markers in clinical practice.
- Informs clinicians about the specific roles of various TM in different cancer types.
- Underscores the need for cautious interpretation of TM results, especially in the presence of benign conditions.